KR890012670A - 항바이러스 배합물 - Google Patents

항바이러스 배합물 Download PDF

Info

Publication number
KR890012670A
KR890012670A KR1019890001620A KR890001620A KR890012670A KR 890012670 A KR890012670 A KR 890012670A KR 1019890001620 A KR1019890001620 A KR 1019890001620A KR 890001620 A KR890001620 A KR 890001620A KR 890012670 A KR890012670 A KR 890012670A
Authority
KR
South Korea
Prior art keywords
interferon
component
hybrid
alanyl
acetyl
Prior art date
Application number
KR1019890001620A
Other languages
English (en)
Other versions
KR0131077B1 (ko
Inventor
강게미 제이.데이비드
호크켑펠 하인쯔-쿠르트
Original Assignee
에른스트 알테르
시비-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에른스트 알테르, 시비-가이기 에이지 filed Critical 에른스트 알테르
Publication of KR890012670A publication Critical patent/KR890012670A/ko
Application granted granted Critical
Publication of KR0131077B1 publication Critical patent/KR0131077B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.

Description

항바이러스 배합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 성분 A로서 구조가 인간 인터페론-α-D 및 -α-B 유전자단편으로부터 유도된 잡종 인터페론 및 성분 B로서 하나이상의 염-형성 그룹을 갖는 뮤라밀 팹티드 또는 뮤라밀팹티드의 약제학적으로 허용되는 염을 약제학적으로 허용되는 담체와 함께 함유하는 약제학적 배합제제.
  2. 제1항에 있어서, 성분 A가 총 166개의 아미노산을 갖는 잡종 α-인터페론이고 인간의 림프아세포 또는 백혈구 인터페론 α-B 또는 -α-D의 아미노산 서열과 아미노산의 조성 및 수가 상응하는 4개의 서열, 즉 인터페론-α-B의 아미노산 1-60, 인터페론 -α-B 또는 -α-D의 아미노산 61-92, 인터페론-α-B 또는 -α-D의 아미노산 93-150 및 인터페론 α-B의 또는 -α-D의 아미노산 151-166로 구성되며 각 잡종은 인터페론 -α-B 및 인터페론-α-D의 서열 중 허느 하나를 하나이상 갖는 제제.
  3. 제1항 또는 제2항에 있어서, 성분 A가 B₁B₂B₃D₄, B₁B₂D₃B₄, B₁B₂D₃D₄, B₁D₂B₃D₄, B₁D₂D₃B₄, B₁D₂D₃D₄, 및 B₁D₂B₃B9D선택된 잡종 α-인터페론 폴리펩티드인 제제.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 성분 B가 N-아세틸-뮤라밀-L-알라닐-D-이소글루타민, N-아세틸-뮤라밀-L-트레오닐-D-이소글루타민, N-아세틸-데메틸류라밀-L-알라닐-D-이소글루타민 또는 N-아세틸-뮤라밀-L-알라닐-D-이소글루타미닐-L-알라닐-2-(1,2-디팔리토일-Sn-글리세로-3-하이드로시포스포릴옥시)-에틸-아미드 및 이의 약제학적으로 허용되는 염인 제제.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 성분 A가 잡종 α-인터페론 폴리펩티드 B₁D₂B₃B₄인 제제.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, 성분 B가 N-아세틸-뮤라밀-L-알라닐-이소글루타미닐-L-알라민-2-(1,2-디팔미토일-Sn-글리세로-3-하이드록시포스포릴옥시)-에틸아미드의 약제학적으로 허용되는 염인 제제.
  7. 제1항에 있어서, 성분 A로서 잡종 α-인터페론 폴리펩티드 B1D2B3B4와 성분 B로서 N-아세틸-뮤라밀-L-알라닐-D-이소글루타미닐-L-알라닐-2-(1,2-디팔미토일-Sn-글리세로-3-하이드록시포스포릴옥시)-에틸아미드의 약제학적으로 허용되는 염과의 배합물(여기에서 B 대 A의 중량비는 1/1 내지 100/1이다)을 항바이러스 유효량 및 대식세포 활성량으로 함유하는, 온혈동물의 바이러스에 의한 감염치료용 또는 대식세포의 활성화용 제제.
  8. 제1항 내지 제6항 중 어느 한 항에 있어서, B 대 A의 중량비가 1/1 내지 100/1인 제제.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, 약제학적으로 허용되는 담체가 합성 포스파티딜콜린 및 합성 포르파티딜 세린의 약제학적으로 허용되는 염으로부터 제조된 리포좀을 함유하는 제제.
  10. 성분 A로서 구조가 인간 인터페론-α-D 및 α-B유전자 단편으로부터 유도된 잡종 α-인터페론과 성분 B로서 뮤라밀 팹티드를 항 바이러스 유효량 또는 전이형성 억제량으로 B 대 A의 중량비가 0.4/1 내지 400/1이 되도록 온혈동물에게 투여함을 특징으로 하여, 바이러스 또는 종양으로 인한 질환으로 고통받는 인간을 포함하는 온혈동물을 치료하는 방법.
  11. 제10항에 있어서, 성분 A로서 잡종 α-인터페론 폴리팹티드 B1D2B3B4와 성분 B로서 N-아세틸-뮤라밀-L-알라닐-D-이소글루타미닐-L-알라닌-2-(1,2-디팔미토일-Sn-글리세로-3-하이드록시포스포릴옥시)-에틸-아미드와의 배합물(여기에서 B 대 A의 중량비는 1/1 내지 100/1이다)을 대식세포 활성량 또는 항바이러스 유효량으로 온혈동물에게 투여함을 특징으로 하여, 온혈동물의 대식세포를 활성화시키거나 헤르페스비리데(Herpesviridae)로 인한 감염을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890001620A 1988-02-13 1989-02-13 항바이러스 배합물 KR0131077B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888803365A GB8803365D0 (en) 1988-02-13 1988-02-13 Antiviral combination
GB8803365 1988-02-13
CH8803365 1988-02-13

Publications (2)

Publication Number Publication Date
KR890012670A true KR890012670A (ko) 1989-09-18
KR0131077B1 KR0131077B1 (ko) 1998-04-17

Family

ID=10631664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890001620A KR0131077B1 (ko) 1988-02-13 1989-02-13 항바이러스 배합물

Country Status (15)

Country Link
US (1) US5137720A (ko)
EP (1) EP0329609B1 (ko)
JP (1) JP2781191B2 (ko)
KR (1) KR0131077B1 (ko)
AT (1) ATE99953T1 (ko)
AU (1) AU623876B2 (ko)
CA (1) CA1336578C (ko)
DE (1) DE68912155T2 (ko)
DK (1) DK62089A (ko)
GB (1) GB8803365D0 (ko)
IE (1) IE63493B1 (ko)
IL (1) IL89248A (ko)
NZ (1) NZ227944A (ko)
PH (1) PH26919A (ko)
ZA (1) ZA891053B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW218846B (ko) * 1992-04-07 1994-01-11 Ciba Geigy
US5932208A (en) * 1993-03-19 1999-08-03 Vacsyn S.A. Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
FR2702659B1 (fr) * 1993-03-19 1995-08-25 Vacsyn Sa Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
US5461512A (en) * 1993-11-30 1995-10-24 Eastman Kodak Company Zoom camera lens having three moving groups
DK0708085T3 (da) * 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US20080317836A1 (en) * 2007-06-19 2008-12-25 Discovery Partners Llc Topical compositions for anti-aging skin treatment
RU2488405C1 (ru) * 2012-07-17 2013-07-27 Илья Александрович Марков Лекарственное средство, обладающее противовирусным, противовоспалительным, иммуномодулирующим и обезболивающим действием, для местного и наружного применения - герпферон 2
KR101658048B1 (ko) 2014-06-25 2016-09-20 한국생명공학연구원 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS616000A (ja) * 1984-06-21 1986-01-11 木下　菊巳 回転色合せ盤
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
AU603820B2 (en) * 1986-08-13 1990-11-29 Takeda Chemical Industries Ltd. Antitumor agent

Also Published As

Publication number Publication date
IL89248A0 (en) 1989-09-10
ZA891053B (en) 1989-10-25
GB8803365D0 (en) 1988-03-16
US5137720A (en) 1992-08-11
JPH021410A (ja) 1990-01-05
KR0131077B1 (ko) 1998-04-17
DE68912155D1 (de) 1994-02-24
DK62089D0 (da) 1989-02-10
AU623876B2 (en) 1992-05-28
EP0329609A2 (en) 1989-08-23
JP2781191B2 (ja) 1998-07-30
IE890435L (en) 1989-08-13
PH26919A (en) 1992-12-03
DE68912155T2 (de) 1994-06-16
EP0329609B1 (en) 1994-01-12
DK62089A (da) 1989-08-14
NZ227944A (en) 1991-08-27
IE63493B1 (en) 1995-05-03
EP0329609A3 (en) 1990-05-16
CA1336578C (en) 1995-08-08
AU2894389A (en) 1989-08-17
IL89248A (en) 1994-01-25
ATE99953T1 (de) 1994-01-15

Similar Documents

Publication Publication Date Title
KR890012670A (ko) 항바이러스 배합물
ES2210864T5 (es) Uso de un interferon de consenso para reducir los efectos secundarios del tratamiento con interferon en hepatitis virica.
EP0858343B1 (en) Continuous low-dose cytokine infusion therapy
US6007805A (en) Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
ES2418833T3 (es) Formulaciones líquidas de interferón estabilizadas
CA2120944A1 (en) Stabilization of human interferon
CA1322713C (en) Compositions and methods for modulating the effect of tnf and il-1
Ross et al. Interferon treatment of cutaneous T‐cell lymphoma
Brunda et al. Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases
BR1100637A (pt) "vìrus de herpes de perus (hvt) recombinante, hvt recombinante, sequência de ácido nucléico, molécupara a preparação de um hvt recombinante, cultura uma vacina, processo para a preparação de uma composição de vacina, farmacêutica ou diagnóstica e anti-soro"
NO169638C (no) Formuleringsblanding med stabiliserende virkning paa alfa-interferon
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
OLESZAK et al. Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells
JP3496937B2 (ja) コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
EP0225759B1 (en) Interferon compositions
Turano et al. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine.
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
Sehgal et al. Interferon and its inducers
HUGHES et al. Do the interferons act singly or in combination?
EP0956040B1 (en) Stimulation of host defense mechanisms against viral challenges
Werenne et al. Antiviral effect of bacterially produced human interferon (Hu-IFNα2) against experimental vaccinia infection in calves
CA1336491C (en) Antiviral pharmaceutical composition
Eppstein et al. Liposomal interferon-β: sustained release treatment of simian varicella virus infection in monkeys
Cantell et al. Circulating interferon in rabbits after simultaneous intramuscular administration of human alpha and gamma interferons
Cerruti et al. Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20081126

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee